Join us at Acute & Chronic Leukemias: Practical Applications 2023 on Oct. 6-7 in Orlando, FL (or via livestream). This year’s conference features interactive case presentations with panels of experts weighing in on pivotal treatment issues. Register here: tinyurl.com/ykcnhbhh
Mark Litzow retweeted
📣 #ESHALL2023 STARTS IN 1 MONTH!
Don’t delay! REGISTER NOW & join us on May 19-21, 2023 in Berlin 🇩🇪
➡ bit.ly/3JJxkXm
3rd Translational Research Conference:
ACUTE LYMPHOBLASTIC LEUKAEMIA
Chairs: @CoolsJn, @DombretHerve, @AdeleKFielding, @MRLitzow
#ESHCONFERENCES #LEUsm
Please consider attending the 3rd Translational Research Conference on ALL in Berlin May 19-21, 2023. Great line up of translational and clinical talks at #ESHALL2023.
Randomizes trial reported at ASCO shows benefit of early integrated palliative care for patients undergoing induction chemotherapy for AML!
meetinglibrary.asco.org/reco…
via @NYTimes, interesting article on unreliability of many antibody tests for SARS-COV-2. nytimes.com/2020/04/24/healt…
One silver lining of the pandemic...... nationalgeographic.com/scien…
A lay statement from the New York Times on the unique pulmonary physiology of COVID-19. nytimes.com/2020/04/20/opini…
Global Concert to celebrate coronavirus workers finale song youtube.com/watch?v=SYJCYr1I…
Yes, correct, it was R-ibrutinib. Thanks for clarifying!
Big year for CLL at ASH 2018! Alliance-led NCTN trial shows Ibrutinib superior to BR in elderly (Plenary session) and ECOG-ACRIN-led NCTN trial shows superiority of Ibrutinib over FCR (LBA Session). And Michael Hallek is giving Ham Wasserman lecture on CLL. @ASH_hematology
#MayoFacDev at the Twitter class with one of my first Tweets @erhall1
@akeithstewart Keith, I joke that I became a hematologist because we don't have to deal with surgeons much! Mark @MRLitzow






